Moderna, Inc.'s Stock Analysis

Moderna Reports 2025 Revenue and Expense Projections

Moderna, Inc. anticipates approximately $1.9 billion in revenue for the fiscal year ended December 31, 2025, which is $100 million above the midpoint of its previous guidance. The company expects GAAP operating expenses to be between $5.0 billion and $5.2 billion, improving its forecast by $200 million. Additionally, it projects a year-end cash balance of around $8.1 billion, which includes a recent $1.5 billion term loan drawdown. Full financial details will be disclosed during the earnings call scheduled for February 13, 2026.

For 2026, Moderna is targeting up to 10% revenue growth and aims to reduce operating expenses to approximately $4.9 billion. The company is also advancing its pipeline, with potential approvals for seasonal flu vaccines and combination products expected in 2026, alongside pivotal trial data readouts in oncology and rare diseases. Key upcoming events include a presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, and the fourth-quarter earnings call on February 13, 2026.

Jan 12, 2026 07:01:10

Moderna Reports 2025 Progress and Future Growth Plans

In 2025, Moderna achieved significant milestones, including securing multiple regulatory approvals and launching three approved commercial products. The company expects revenue between $1.6 billion and $2.0 billion, driven by strong uptake of its vaccines, particularly mNEXSPIKE, which captured a notable share of the U.S. COVID vaccination market. Moderna also expanded its global manufacturing capabilities and formed strategic partnerships in key international markets, enhancing its presence and revenue visibility.

Looking ahead, Moderna plans to build on its success by diversifying its product portfolio with a focus on seasonal vaccines, oncology, and rare diseases. The company anticipates continued sales growth, aiming for up to 10% revenue growth in 2026, supported by new product launches and geographic expansion. Additionally, Moderna's disciplined financial management has improved its cash position, with expectations of reduced operating expenses and a path towards cash breakeven by 2028.

Jan 05, 2026 09:04:27

Moderna Secures $1.5 Billion Credit Facility Agreement

Moderna, Inc. has entered into a Credit and Guaranty Agreement providing a total credit facility of $1.5 billion. This includes an initial term loan of $600 million and delayed draw term loans amounting to $900 million, with specific conditions tied to regulatory milestones. The loans will bear interest based on the Secured Overnight Funding Rate plus a margin of 5.50% or the base rate plus a margin of 4.50%. The maturity date for these loans is set for November 24, 2030.

The Credit Agreement includes a minimum liquidity requirement, mandating at least $500 million in cash and cash equivalents weekly, increasing to $750 million if over $1 billion is drawn. This financial covenant is not applicable if the company's market capitalization exceeds $5 billion. The loans are guaranteed by various international subsidiaries and secured by an all-asset collateral grant, subject to customary exceptions.

Nov 24, 2025 16:29:39

Moderna Announces Pipeline Progress and Revenue Growth Targets

Moderna has outlined its pipeline progress and strategic business updates during its Analyst Day on November 20, 2025. The company targets up to 10% revenue growth in 2026, driven by expanding its seasonal vaccine franchise from three to six approved products by 2028. Moderna plans to leverage cash from existing products to fund investments in oncology and rare disease programs, while also enhancing its commercial infrastructure to support geographic expansion and new product launches.

Financially, Moderna has reduced its expected cash costs for 2026 and 2027 to approximately $4.2 billion and between $3.5 to $3.9 billion, respectively. The company has also secured a five-year term loan facility for up to $1.5 billion to strengthen its balance sheet. Moderna anticipates a year-end cash and investment balance for 2025 in the range of $7.1 to $7.6 billion, reflecting increased liquidity and financial flexibility as it aims for cash breakeven by 2028.

Nov 20, 2025 07:12:22

Moderna Shareholders Approve Stock Option Exchange Program

On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where a quorum was present. Shareholders approved a one-time stock option exchange program specifically for non-Executive Committee employees. This decision reflects the company's strategy to manage employee compensation through stock options.

Additionally, shareholders approved a proposal to adjourn the Special Meeting if necessary, allowing for further solicitation and voting on the Option Exchange Proposal. There were no broker non-votes recorded for any of the proposals presented during the meeting, and no other matters were discussed or voted on.

Nov 13, 2025 16:19:14

Moderna Reports Q3 2025 Financial Results and Updates

Moderna, Inc. reported total revenue of $1.0 billion for the third quarter of 2025, reflecting a 45% decrease from $1.9 billion in the same period last year. The decline was largely attributed to a significant reduction in COVID vaccine sales, which fell by 47% due to decreased vaccination rates in the U.S. The company narrowed its projected revenue range for 2025 to between $1.6 billion and $2.0 billion and improved its expected GAAP operating expenses by $0.7 billion, now anticipating expenses of $5.2 billion to $5.4 billion. As of September 30, 2025, Moderna reported a cash balance of $6.6 billion, down from $7.5 billion at the end of the previous quarter.

In terms of product performance, Moderna recorded $971 million in COVID vaccine sales, with $781 million from U.S. sales and $190 million internationally. The company has received approval for its new COVID vaccine formula in 40 countries and has seen initial sales of its RSV vaccine, mRESVIA, totaling $2 million. Additionally, Moderna is advancing its pipeline with several late-stage vaccine candidates and has made progress in oncology and rare disease therapeutics. The company plans to provide further updates on its business and pipeline during its Analyst Day on November 20, 2025.

Nov 06, 2025 07:03:01

Moderna Reports Q2 2025 Financial Results and Updates Guidance

Moderna, Inc. reported second quarter revenues of $142 million for 2025, a 41% decrease from $241 million in the same quarter of 2024, primarily due to lower COVID vaccine sales. The company recorded a GAAP net loss of $800 million, or $(2.13) per share, compared to a net loss of $(1.3) billion, or $(3.33) per share in Q2 2024. Moderna updated its projected revenue range for 2025 to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end due to delayed deliveries. The company expects to maintain a year-end cash balance of approximately $6 billion and has improved its expected operating expenses for the year by about $400 million to a range of $5.9 to $6.1 billion.

In addition to financial results, Moderna announced three recent FDA approvals and positive Phase 3 results for its seasonal influenza vaccine. The company reported $114 million in Spikevax sales for Q2 2025, with expectations for increased demand in the latter half of the year. R&D expenses decreased by 43% to $700 million, attributed to reduced clinical trial and manufacturing costs. Moderna also announced a workforce reduction of about 10% and highlighted ongoing advancements in its pipeline, including vaccines for RSV, norovirus, and various oncology therapeutics.

Aug 01, 2025 07:02:12

Moderna Reports Q1 2025 Loss and Revenue Decline

Moderna, Inc. announced its financial results for the first quarter of 2025, reporting revenues of $108 million and a GAAP net loss of $1.0 billion, resulting in a loss per share of $2.52. The revenue decline from $167 million in the same quarter of 2024 was attributed to lower vaccination rates and a shift in COVID-19 demand to a seasonal market. The company reaffirmed its expected revenue range for 2025 of $1.5 to $2.5 billion and projected a year-end cash balance of approximately $6 billion.

The company is also implementing cost reductions, aiming to decrease operating expenses by $1.4 to $1.7 billion by 2027. Moderna is advancing up to 10 products towards approval, with a focus on oncology candidates and respiratory vaccines. Recent sales included $84 million from its COVID-19 vaccine, Spikevax®, and $2 million from its RSV vaccine, mRESVIA®. The company's cash position as of March 31, 2025, stood at $8.4 billion, down from $9.5 billion at the end of 2024.

May 01, 2025 06:31:33

Moderna Reports Q4 2024 Revenue Drop and Increased Losses

Moderna reported fourth quarter revenues of $1.0 billion, a significant decline from $2.8 billion in the same period last year, primarily due to lower sales of its COVID-19 vaccine. The company faced a GAAP net loss of $(1.1) billion, which included non-cash charges related to manufacturing resizing, and a loss per share of $(2.91), compared to earnings per share of $0.55 in Q4 2023. For the full year 2024, total revenues were $3.2 billion, down from $6.8 billion in 2023, reflecting a shift to a seasonal market for COVID-19 vaccines and reduced sales volumes in international markets. However, the company ended the year with a cash position of $9.5 billion, an increase from $9.2 billion at the end of the previous quarter, indicating some liquidity improvement amid operational challenges.

In terms of operational updates, Moderna successfully submitted three investigational mRNA products for regulatory approval, including a next-generation COVID vaccine and an RSV vaccine, which could support future revenue streams. The company also achieved a 27% reduction in costs compared to the previous year, with significant decreases in research and development as well as selling, general, and administrative expenses. However, the overall net loss for 2024 was $(3.6) billion, an improvement from the $(4.7) billion loss in 2023, but the decline in revenues and ongoing operational challenges highlight the need for continued focus on cost management and product approvals in the upcoming year.

Feb 14, 2025 06:30:34

Moderna Reports $3.0 Billion Sales and Cost Reductions

Moderna announced that it achieved product sales of approximately $3.0 to $3.1 billion for 2024, with a significant cash balance of about $9.5 billion at year-end. The company plans to reduce cash costs by $1.0 billion in 2025 and anticipates a projected revenue range of $1.5 to $2.5 billion for that year, largely driven by vaccine sales. The company is focusing on approvals across ten prioritized programs, including its RSV vaccine and next-generation COVID-19 vaccine.

On the downside, Moderna updated its expected ending cash balance for 2025 to approximately $6.0 billion, indicating a decrease from its current balance. Additionally, the Data Safety Monitoring Board for its cytomegalovirus vaccine indicated that early efficacy criteria were not met, although the study will continue. The company faces uncertainties in its pipeline with potential delays in data readouts and approvals, which could impact future revenue.

Jan 13, 2025 07:03:24